Initiate open-label extension trial with 25 mg daily dosing
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 10 Aug 2023
- Due
- 31 Mar 2024
- Delivered
- January 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Initiation of OLE trial with 25 mg daily dosing expected in Q1 2024”
What we found
Evidence strength A What the grades mean
The company initiated the open-label extension trial with 25 mg daily dosing in January 2024, with the first patient dosed in March 2024, successfully meeting the Q1 2024 deadline.
-
A Larimar Therapeutics, Inc. 8-K filed 2024-05-09
“First patient dosed in open label extension (OLE) study with 25 mg daily dosing of nomlabofusp” ✓ confirmed on the page
-
A Larimar Therapeutics, Inc. 10-Q filed 2024-05-09
“In January 2024, we initiated the OLE trial, discussed above, evaluating daily subcutaneous injections of 25 mg of nomlabofusp” ✓ confirmed on the page
Market reaction: the shares moved -8.3% against the S&P 500 over the three sessions around the disclosure (8 May 2024 to 13 May 2024). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- OLE trial
- Target
- 25 mg
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: subject to regulatory review
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Late”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Larimar Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-LRMR-002972 · Corrections policy